Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (Pegasys®) in Patients With HBeAg-Positive Chronic Hepatitis B
Conditions
Interventions
Peginterferon alfa-2a
Locations
3
China
Beijing, China
Guangzhou, China
Shanghai, China
Start Date
November 1, 2003
Primary Completion Date
November 1, 2005
Completion Date
November 1, 2005
Last Updated
November 2, 2016
NCT04166266
NCT06550622
NCT05922306
NCT05870969
NCT04856085
NCT04780204
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions